Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

Introduction: In the phase 3 KEYNOTE-604 study (NCT03066778), pembrolizumab plus etoposide and platinum chemotherapy (EP) significantly (p = 0.0023) improved progression-free survival versus placebo plus EP in previously untreated extensive-stage SCLC (ES-SCLC). We present health-related quality of...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Hye Ryun Kim, MD, PhD, Mark M. Awad, MD, PhD, Alejandro Navarro, MD, Maya Gottfried, MD, Solange Peters, MD, PhD, Tibor Csőszi, MD, Parneet K. Cheema, MD, Delvys Rodriguez-Abreu, MD, PhD, Mirjana Wollner, MD, James Chih-Hsin Yang, MD, PhD, Julien Mazieres, MD, PhD, Francisco J. Orlandi, MD, Alexander Luft, MD, PhD, Mahmut Gümüş, MD, Terufumi Kato, MD, Gregory P. Kalemkerian, MD, Yiwen Luo, PhD, Melissa L. Santorelli, PhD, MPH, M. Catherine Pietanza, MD, Charles M. Rudin, MD, PhD
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2023-11-01
Serier:	JTO Clinical and Research Reports
Fag:	Pembrolizumab Chemotherapy Extensive-stage small-cell lung cancer Health-related quality of life Patient-reported outcomes
Online adgang:	http://www.sciencedirect.com/science/article/pii/S2666364323001157
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!